Ballentine Partners LLC Buys New Position in Align Technology, Inc. $ALGN

Ballentine Partners LLC purchased a new position in Align Technology, Inc. (NASDAQ:ALGN) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 1,548 shares of the medical equipment provider’s stock, valued at approximately $293,000.

Several other hedge funds also recently modified their holdings of ALGN. Counterpoint Mutual Funds LLC bought a new position in Align Technology during the second quarter worth $325,000. Argent Capital Management LLC grew its position in Align Technology by 163.3% in the 2nd quarter. Argent Capital Management LLC now owns 113,417 shares of the medical equipment provider’s stock worth $21,473,000 after purchasing an additional 70,344 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Align Technology by 84.1% during the 2nd quarter. GAMMA Investing LLC now owns 1,458 shares of the medical equipment provider’s stock worth $276,000 after purchasing an additional 666 shares during the period. Park Avenue Securities LLC raised its position in shares of Align Technology by 11.2% during the second quarter. Park Avenue Securities LLC now owns 2,668 shares of the medical equipment provider’s stock valued at $505,000 after buying an additional 269 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its position in shares of Align Technology by 42.2% during the second quarter. Farther Finance Advisors LLC now owns 310 shares of the medical equipment provider’s stock valued at $59,000 after buying an additional 92 shares during the last quarter. 88.43% of the stock is owned by institutional investors.

Align Technology Stock Up 1.0%

Shares of Align Technology stock opened at $126.19 on Monday. Align Technology, Inc. has a 12-month low of $122.00 and a 12-month high of $259.01. The stock has a market capitalization of $9.15 billion, a P/E ratio of 21.28, a price-to-earnings-growth ratio of 1.42 and a beta of 1.65. The company has a 50-day simple moving average of $147.30 and a 200 day simple moving average of $167.06.

Align Technology (NASDAQ:ALGN) last issued its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $2.49 earnings per share for the quarter, missing the consensus estimate of $2.57 by ($0.08). The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.06 billion. Align Technology had a return on equity of 13.36% and a net margin of 11.04%.Align Technology’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company posted $2.41 earnings per share. Align Technology has set its Q3 2025 guidance at EPS. On average, equities analysts anticipate that Align Technology, Inc. will post 7.98 earnings per share for the current year.

Align Technology announced that its Board of Directors has approved a share repurchase program on Tuesday, August 5th that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the medical equipment provider to reacquire up to 2% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ALGN. Mizuho set a $210.00 price target on Align Technology in a research note on Thursday, July 31st. Morgan Stanley reissued an “equal weight” rating and set a $154.00 price objective (down previously from $249.00) on shares of Align Technology in a report on Thursday, July 31st. Wells Fargo & Company cut their target price on Align Technology from $246.00 to $199.00 and set an “overweight” rating for the company in a research note on Thursday, July 31st. Stifel Nicolaus decreased their price target on shares of Align Technology from $275.00 to $200.00 and set a “buy” rating on the stock in a research note on Thursday, July 31st. Finally, Evercore ISI boosted their price target on shares of Align Technology from $200.00 to $220.00 and gave the company an “outperform” rating in a report on Wednesday, July 9th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Align Technology presently has an average rating of “Moderate Buy” and an average target price of $215.00.

Insider Buying and Selling

In other Align Technology news, CEO Joseph M. Hogan purchased 7,576 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The stock was purchased at an average cost of $131.49 per share, with a total value of $996,168.24. Following the acquisition, the chief executive officer directly owned 184,945 shares of the company’s stock, valued at approximately $24,318,418.05. This trade represents a 4.27% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 0.66% of the stock is currently owned by company insiders.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.